South Africa bets on biannual HIV prevention with $72M Lenacapavir rollout

South Africa announced a R1.3 billion ($72 million) rollout to deploy Lenacapavir, a long-acting HIV prevention injection given twice a year, across 360 clinics in 24 high-burden districts, aiming to reach about 1 million people by 2027 with support from the Global Fund and CIFF; the program seeks affordable generics via a voluntary license by 2027 and a broader push to manufacture 60% of Africa's medical products locally by 2040.